VERAXA Biotech, Voyager Acquisition File SEC Forms for $1.64B Merger Expected Q4 2025

VERAXA Biotech AG is advancing its planned merger with Voyager Acquisition Corp., filing a Form F-4 registration statement with the SEC as a key step towards a NASDAQ listing and an estimated valuation of $1.64 billion. The merger agreement, approved unanimously by both companies' boards, involves VERAXA contributing approximately $1.3 billion in equity value and its shareholders exchanging their shares for about 130 million ordinary shares in the merged entity, with no cash payouts to current VERAXA shareholders or management. Post-merger, VERAXA will gain access to up to $253 million in cash held by Voyager, supporting its strategic focus on oncology therapies. The transaction is expected to close in the fourth quarter of 2025, pending shareholder approval and customary closing conditions. Xlife Sciences AG, holding a 19% stake in VERAXA, highlights this merger as a significant milestone in VERAXA's journey to becoming a global player in the life sciences sector. The Form F-4 filing includes detailed information about Voyager's business, VERAXA's drug pipeline, technology, and intellectual property, underscoring the companies' combined growth potential.